Document is current
Any future updates will be listed below
-
Authors
Fankhauser, Reilly G. https://orcid.org/0000-0001-6318-4255
Johnson, Douglas B.
Moslehi, Javid J.
Balko, Justin M. https://orcid.org/0000-0002-4263-5974
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (5R01HL156021-04, 5R01HL155990-04, 5R01HL156021-04, 5R01HL155990-04, 5R01HL141466-05, NIH P01 HL141084, NIH R01 HL160688)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (5R01CA227481-05, 5P30CA068485-29, 5R01CA227481-05)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32GM007347)
American Heart Association (25PRE1375723)
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 10 March 2025
First Online: 7 May 2025
Competing interests
: R.G.F. has no conflicts of interest to disclose. J.J.M. has consulting or advisory roles for Pfizer, Novartis, Bristol Myers Squibb, Deciphera, Takeda, AstraZeneca, Regeneron, Myovant, Silverback Therapeutics, Kurome Therapeutics, Kiniksa Pharmaceuticals, Daiichi Sankyo, BeiGene, IQVIA, AskBio, Labcorp, Paladin, Bitterroot Bio, Repare Therapeutics and Cytokinetics. J.J.M. is a co-inventor of a patent related to the use of abatacept in the treatment of ICI-myocarditis. D.B.J. has served on advisory boards or as a consultant for AstraZeneca, BMS, Jackson Laboratory, Merck, Novartis, Pfizer, Targovax and Teiko and has received research funding from BMS and Incyte. J.M.B. reports grants from the NIH/NCI, the DOD, Susan G. Komen and the BCRF during the conduct of the study. J.M.B. also reports grants from Genentech and Incyte and personal fees from AstraZeneca and Eli Lilly outside the submitted work; in addition, J.M.B. has a patent for MHC-I and MHC-II expression to predict immunotherapy outcomes issued.
